Company Analysis

Inhibikase Therapeutics, Inc. (IKT)

Nasdaq: IKT · Biological Products, (No Diagnostic Substances) · Wilmington, DE · filing with the SEC since 2018
Grade4.3
◀ Past 2.4● Present 4.1▶ Future 5.7
4 est.

Income statement, as filed

In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Report filedMar 26, 2026Mar 27, 2025Mar 27, 2024Mar 31, 2023Mar 31, 2022Mar 31, 2021
Revenue·0260,501123,4403,100,605698,468
For lenders
Net interest income3,715,0941,069,1821,060,90974,453-19,923·
Research and development29,793,14617,210,54813,618,34812,034,98511,359,104893,802
Selling, general and administrative23,555,07911,378,5206,731,9456,217,0636,507,6412,623,158
Total costs and expenses51,974,28328,589,06820,350,29318,252,04817,866,7453,516,960
Operating income-51,974,283-28,589,068-20,089,792-18,128,608-14,766,140-2,818,492
Interest expense····19,92329,402
Income before income taxes-48,259-27,520····
Income tax expense00····
Net income-48,259,189-27,519,886-19,028,883-18,054,155-14,786,063-2,847,894
Earnings per share, basic-0.49-1.16-3.16r-3.7765rb-4.2669b·
Earnings per share, diluted-0.49-1.16-3.16r-3.7765rb-4.2669b·
Earnings per share, basic and diluted····-4.2669b-1.8437b
Weighted average shares, basic98,310,19023,712,2206,028,210r4,786,179rb3,456,713b·
Weighted average shares, diluted98,310,19023,712,2206,028,210r4,786,179rb3,456,713b·
Weighted average shares, basic and diluted····3,456,713b1,559,022b
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the change of share basis of Aug 2020.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Net interest income interest earned less interest paidus-gaap:InterestIncomeExpenseNet
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative the cost of selling and of running the companyus-gaap:SellingGeneralAndAdministrativeExpense
Total costs and expenses every operating cost, the cost of revenue includedus-gaap:CostsAndExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest expense what its borrowing costus-gaap:InterestExpense
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Earnings per share, basic and diluted net income per share, where both counts are the sameus-gaap:EarningsPerShareBasicAndDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Weighted average shares, basic and diluted the average count, where both counts are the sameus-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
SI Assistanton IKT · research, not advice